Oxaliplatin, irinotecan, bevacizumab followed by docetaxel, bevacizumab in inoperable gastric cancer: Final efficacy results of a multicenter phase II trial (AGMT Gastric-3) of the arbeitsgemeinschaft Medikamentöse tumortherapie (AGMT).
Ewald Woell
Honoraria - Pfizer; Roche; Sanofi
Felix Keil
No relevant relationships to disclose
Josef Thaler
No relevant relationships to disclose
Birgit Gruenberger
Honoraria - Roche
Michael Hejna
No relevant relationships to disclose
Wolfgang Eisterer
No relevant relationships to disclose
Michael A. Fridrik
Honoraria - Roche
Franz Romeder
No relevant relationships to disclose
Richard Greil
No relevant relationships to disclose